Systematic Review of Ketamine for Depression in Adult Cancer Patients

Fourteen studies, including randomized controlled trials and cohort studies, were identified from 3,036 unique records. This systematic review, authored by Yogendra Singhal and registered with PROSPERO, assesses the efficacy and safety of ketamine for treating depression in adult cancer patients. The document was last updated on May 29, 2026.

Use Cases

• Assessing the rapid antidepressant effects of ketamine based on the review of clinical trial outcomes.
• Evaluating short-term safety profiles based on reported side effects like fatigue and dissociation.
• Identifying research gaps for long-term outcomes and dosing strategies based on the review's conclusions.

Strengths

• Follows PRISMA guidelines and is registered with PROSPERO (CRD42024603120).
• Synthesizes evidence from 14 studies identified through a search of 6 major databases.
• Explicitly focuses on adult cancer patients, a specific clinical population.

Limitations

• The dataset is a 71.3 KB DOCX file, indicating a very limited textual scope rather than raw research data.
• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for quantitative analysis.

Provenance

Source

figshare

Collection Method

Systematic literature review conducted across PubMed, MEDLINE, Cochrane CENTRAL, Embase, Web of Science, and PsycINFO.

Freshness

Last updated 2026-05-29 17:29:24; freshness should be verified.